Iovance Biotherapeutics is trading 11.98% down at $8.36 after updated Phase 2 lung-cancer results. - The study reported a 24.6% response rate among 69 patients, compared with 25.6% previously reported among 39 patients; the update also highlighted stronger results in a retrospectively selected subgroup. - Shares closed at $9.56 on October 29, down 35.45%, after Thursday’s sharp selloff, then fell further during Friday trading on October 30. The trial update was the clearest reported catalyst for the continued decline.